Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database., PMID:40055991
Autoimmune Polyglandular Syndrome Type 3: A Case Report., PMID:39834989
Association between glucose-lowering drugs and circulating insulin antibodies induced by insulin therapy in patients with type 2 diabetes., PMID:39099829
In Silico Assessment of Biomolecule Reactivity with Leachables., PMID:38942477
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment., PMID:38876181
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study., PMID:38558508
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial., PMID:38420944
Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3., PMID:38185739
Insulin Edema Associated With Glargine., PMID:38116161
Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial., PMID:37732487
Development and Characterization of Guinea Pig Anti-Insulin Polyclonal Antibody., PMID:37713062
Using real-world evidence data and digital monitoring to analyze the hepatotoxic profiles of biologics across more than two million patients., PMID:37407661
Identifying blood biomarkers for type 2 diabetes subtyping: a report from the ORIGIN trial., PMID:36854916
Diagnostic camouflage: A case report on Latent autoimmune diabetics of adulthood., PMID:36268330
Quantification of Insulin Analogs by Liquid Chromatography-High-Resolution Mass Spectrometry., PMID:36127592
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study., PMID:36114990
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland., PMID:35793041
Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial., PMID:35471721
Production of insulin antibody associated with relapsed hodgkin's lymphoma., PMID:35463857
Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus., PMID:35187770
Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials., PMID:34866291
[Comparison of efficacy and safety of insulin aspart injection Rishulin and NovoRapid for treatment of diabetes: a multicenter, randomized, open-labeled, controlled trial]., PMID:34856687
Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial., PMID:34676424
Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study., PMID:34580638
NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products., PMID:34299526
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications., PMID:36204505
Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies., PMID:34174848
Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial., PMID:34121308
Facilitated Qualitative Determination of Insulin, Its Synthetic Analogs, and C-Peptide in Human Urine by Means of LC-HRMS., PMID:34065812
Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study., PMID:33981301
Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial., PMID:33783964
Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis., PMID:33675117
Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy., PMID:33594405
Development and validation of a method for quantification of human insulin and its synthetic analogues in plasma and post-mortem sera by LC-MS/HRMS., PMID:33592769
Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes., PMID:33469328
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin., PMID:33432547
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis., PMID:35373017
Insulin binding to the analytical antibody sandwich pair OXI-005 and HUI-018: Epitope mapping and binding properties., PMID:33277949
[Efficacy and safety of Changsulin® compared with Lantus® in type 2 diabetes: a phase Ⅲ multicenter, randomized, open-label, parallel, controlled clinical trial]., PMID:33256337
AUTOIMMUNE DIABETES IN A PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS ON ANTI-RETROVIRAL THERAPY WITH LITERATURE REVIEW., PMID:32984521
A UNIQUE CASE OF ATEZOLIZUMAB-INDUCED AUTOIMMUNE DIABETES., PMID:32984519
Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c., PMID:32220551
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial., PMID:32068436
USE OF INHALED INSULIN IN A PATIENT WITH SUBCUTANEOUS INSULIN RESISTANCE SYNDROME: A RARE CONDITION., PMID:31967031
The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus., PMID:31950036
Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism., PMID:31829972
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)., PMID:31804851
Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials., PMID:31769496
Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis., PMID:31758850
Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis., PMID:31718624
For research use only. Not for human or drug use.
